A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients

Canadian Journal of Gastroenterology

Volumn 27, Issue 10, 2013, Pages 587-592

  Sigalet, David L ^a   Kravarusic, Dragan ^b   Butzner, Decker ^a   Hartmann, Bolette ^c   Holst, Jens J ^c   Meddings, Jon ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

3 O methyl glucose; Intestinal permeability; Lactulose; Mannitol; Nutrient absorption

Indexed keywords

AZATHIOPRINE; GLUCAGON LIKE PEPTIDE 2; GLUCOSE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; FEMALE; GLUCOSE ABSORPTION; GLUCOSE TRANSPORT; HUMAN; INTESTINE FUNCTION; MALE; PILOT STUDY; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REMISSION; SCHOOL CHILD; SIGNAL TRANSDUCTION;

3-O-METHYLGLUCOSE; ADOLESCENT; CHILD; CROHN DISEASE; FEMALE; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; LACTULOSE; LONGITUDINAL STUDIES; MALE; MANNITOL; PILOT PROJECTS; POSTPRANDIAL PERIOD; SIGNAL TRANSDUCTION;

EID: 84885585104     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/460958     Document Type: Article

References (43)

1. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996;93:7911-6.
2. Sangild PT, Tappenden KA, Malo C, et al. Glucagon-like peptide 2 stimulates intestinal nutrient absorption in parenterally fed newborn pigs. J Pediatr Gastroenterol Nutr 2006;43:160-7. (Pubitemid 44180499)
3. Cottrell JJ, Stoll B, Buddington RK, et al. Glucagon-like peptide-2 protects against TPN-induced intestinal hexose malabsorption in enterally refed piglets. Am J Physiol Gastrointest Liver Physiol 2006;290:G293-G300.
4. Martin GR, Wallace LE, Sigalet DL. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2004;286:G964-G972. (Pubitemid 38715659)
5. Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol 2003;81:1005-12. (Pubitemid 38045829)
6. Roberge JN, Brubaker PL. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 1991;128:3169-74.
7. Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 1999;45:559-63. (Pubitemid 29447825)
8. Martin GR, Wallace LE, Hartmann B, et al. Nutrient stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2004;288:G431-G438. (Pubitemid 40261740)
9. Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006;130:44-54. (Pubitemid 43049834)
10. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999;277:E937-E947.
11. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005;54:1224-31. (Pubitemid 41192479)
12. Ivory CP, Wallace LE, McCafferty DM, Sigalet DL. Interleukin-10- independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2008;295:G1202-G1210.
13. Sigalet DL, Wallace LE, Holst JJ, et al. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007;293:G211-G221. (Pubitemid 47105173)
14. Martin GR, Meddings JB, Sigalet DL. 3-0 methylglucose absorption in vivo correlates with nutrient absorption and intestinal surface area in experimental short bowel syndrome. J Parenter Enteral Nutr 2003;27:65-70. (Pubitemid 36105646)
15. Bijlsma MF, Peeters RA, Groot JA. Differential in vivo and in vitro intestinal permeability to lactulose and mannitol in animals and humans: A hypothesis. Gastroenterology 1995;108:687-96.
16. Bjarmason I, Macpherson A, Hollander D. Intestinal permeability: An overview. Gastroenterology 1996;108:1581.
17. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78.
18. Meddings J. Barrier dysfunction and Crohn's disease. Ann N Y Acad Sci 2002;915:333-8. (Pubitemid 32059399)
19. Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 2000;119:1740-4. (Pubitemid 32198699)
20. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:362-81.
21. Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L, Holst JJ. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 2000;21:73-80. (Pubitemid 30126045)
22. Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 1999;117:99-105. (Pubitemid 29297625)
23. Xiao Q, Boushey RP, Cino M, Drucker DJ, Brubaker PL. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regulatory Integrative Comp Physiol 2000;278:R1057-R1063. (Pubitemid 30215220)
24. Schmidt PT, Ljung T, Hartmann B, Hare KJ, Holst JJ, Hellstrom PM. Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: Comparison with peptide YY. Eur J Gastroenterol Hepatol 2005;17:207-12. (Pubitemid 40349535)
25. Kravarusic D, Holst J, Wallace LE, Sigalet DL. Effects of inflammation in Crohn's disease on meal stimulated GLP-2 levels. J Pediatr Surg 2006;37(Symposium Proceedings):A134. (Abst)
26. Sandler RS, Jordan MC, Cooper LL. Development of a Crohn's index for survey research. Clin Epidemiol 1988;41:451-8.
27. Otley A, Loonen H, Parekh N, Corey M, Sherman PM, Griffiths AM. Assessing activity of pediatric Crohn's disease: Which index to use? Gastroenterology 1999;116:527-31. (Pubitemid 29106759)
28. Sigalet DL, Martin G, Meddings J, Hartman B, Holst JJ. GLP-2 levels in infants with intestinal dysfunction. Pediatr Res 2004;56:371-6.
29. Sigalet DL, Martin GR, Meddings JB. 3-0 methylglucose uptake as a marker of nutrient absorption and bowel length in pediatric patients. J Parenteral Enteral Nutr 2004;28:158-62. (Pubitemid 38507245)
30. Punati J, Markowitz J, Lerer T, et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis 2008;14:949-54.
31. Robertson MA, Sigalet DL, Holst JJ, Meddings JB, Wood J, Sharkey KA. Intestinal permeability and glucagon-like peptide-2 in children with autism: A controlled pilot study. J Autism Dev Disord 2008;38:1066-71.
32. Jeppesen PB, Hartmann B, Thulesen J, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000;47:370-6.
33. El-Salhy M, Danielsson A, Stenling R, Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J Intern Med 1997;242:413-9. (Pubitemid 27513108)
34. Lomax AE, Linden DR, Mawe GM, Sharkey KA. Effects of gastrointestinal inflammation on enteroendocrine cells and enteric neural reflex circuits. Auton Neurosci 2006;126-127:250-7. (Pubitemid 43816924)
35. O'Hara JR, Ho W, Linden DR, Mawe GM, Sharkey KA. Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitis. Am J Physiol Gastrointest Liver Physiol 2004;287:G998-1007.
36. Hedin CR, Stagg AJ, Whelan K, Lindsay JO. Family studies in Crohn's disease: New horizons in understanding disease pathogenesis, risk and prevention. Gut 2012;61:311-8.
37. Amin H, Holst JJ, Hartmann B, Wallace L, Wright J, Sigalet DL. Functional ontogeny of the proglucagon-derived peptide axis in the premature human neonate. Pediatrics 2008;121:e180-e186.
38. McOmber ME, Ou CN, Shulman RJ. Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults. J Pediatr Gastroenterol Nutr 2010;50:269-75.
39. Martin GR, Beck PL, Sigalet DL. Gut hormones, and short bowel syndrome: The enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol 2006;12:4117-29. (Pubitemid 44376887)
40. Kaji T, Tanaka H, Holst JJ, et al. The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the rat. Eur J Pharmacol 2008;596:138-45.
41. Critch J, Day AS, Otley A, King-Moore C, Teitelbaum JE, Shashidhar H. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012;54:298-305.
42. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007;(1):CD000542.
43. Buchman AL, Katz S, Fang JC, Bernstein CN, bou-Assi SG. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 2010;16:962-73.